An interventional study of ATNC MDD-V1 (Real TMS + Real Cog) and ATNC MDD-V1 (Sham TMS + Real Cog) in Alzheimer's Disease, Dementia and Brain Diseases, sponsored by Advanced Technology & Communications. Recruiting at 11 sites in South Korea. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Advanced Technology & Communications · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies in Alzheimer Disease with a site in Korea, Republic of — 34 open to participants now, 46 under way, 16 of them phase 3. Alzheimer Disease · Korea, Republic of.
Among the 174 studies in Alzheimer Disease with a site in Korea, Republic of, this one is the 86th largest by planned enrollment of the 157 interventional ones that give a count, is one of 5 that started in 2023, is one of 27 with no phase, reaches primary completion later than 18 of the 45 other live ones, and was the 138th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →34 of the 174 studies in Alzheimer Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
ReadyCure Inc. · Sites in Korea, Republic of
Ages 60–85
Eli Lilly and Company · Sites in Korea, Republic of, United States, Japan and 1 more country
Ages 55–85
CKD Bio Corporation · Sites in Korea, Republic of
Ages 55–85
Neumous Inc. · Sites in Korea, Republic of
Ages 50–85
Bristol-Myers Squibb · Sites in Korea, Republic of, United States, Argentina and 23 more countries
Ages 55–90
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 60 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 37 · Phase 3 65 · Phase 4 13
First in 2003; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 206 across the 157 interventional studies, 500 across the 17 observational. Of the 109 that completed or were terminated, 45 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
125 of 174 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Advanced Technology & Communications as lead sponsor.
Advanced Technology & Communications has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
14 of the studies in Alzheimer Disease with a site in Korea, Republic of that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT07239310DeepsonbioNeuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 174 studies in Alzheimer Disease with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.
The ATNC MDD-V1 system is a combined system of Transcranial Magnetic Stimulation and cognitive training and is a non-invasive therapeutic system for the improvement of Alzheimer patients' cognitive function.
A potential participant will undergo screening procedures to confirm eligibility to participate in the study, followed by randomization procedure to one of the study groups - treatment or sham (placebo) Patient will attend the clinic 5 times a week for 6 weeks, approximately an hour every day for treatment/sham. The patient will be required to return to the clinic for follow-up.
Up to 180 patients will be enrolled in up to 11 clinical sites in the Republic Korea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
CDR 1 or GDS 3.
※ For subjects who are excluded from screening based on criteria 5 or 6, if the investigator judges that the subject is likely to be eligible, one repeat screening may be performed.
Exclusion Criteria:
Patients who participated in other clinical trials 3 months before participating in this clinical trial.
※ Subjects who participate in non-interventional studies (such as observational studies) that do not affect the subject's disease or symptoms may be enrolled in the study.
Patients judged by the investigator to be unsuitable for participation in clinical trials for other reasons.
※ If the test subject is unable to visit according to the research plan due to unavoidable personal circumstances during the screening period, it will be treated as a screening dropout, and the patient can participate in the study after re-agreeing according to the future schedule.
Patients with a history of malignant tumors within the last 5 years.
- Participation is possible if more than 5 years have elapsed without recurrence after the decision to be cured (The point of complete removal of the tumor through surgery or the end of chemotherapy, etc.).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ATNC MDD-V1 treatment, synchronized TMS and cognitive training stimulation
Device: ATNC MDD-V1 (Real TMS + Real Cog) · Device: ATNC BN-V1 · Device: ATNC BN-V2
The Control arm subjects will receive daily treatments five days a week for 6 consecutive weeks of Sham treatment of TMS and real cognitive training which is similar to the real treatment in visit frequency and procedure.
Device: ATNC MDD-V1 (Sham TMS + Real Cog) · Device: ATNC BN-V1 · Device: ATNC BN-V2
Synchronized TMS and cognitive stimulation to 6 brain areas.
Also known as: ATNC MDD-V1, Brain Sense & Brain Cog
Sham device, has the same appearance and sound as the real device, combined with real cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
Also known as: sham
The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
Also known as: Brain Navigation System V1
The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
Also known as: Brain Navigation System V2
Alzheimer's Disease Assessment Scale-Cognition Score (Efficacy)
Change from Baseline to 24 weeks in ADAS-Cog score. ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive
Time frame: Week 24
Alzheimer's Disease Assessment Scale-Cognitive(ADAS-cog) Score (Efficacy)
Change from Baseline to 7,12 weeks in ADAS-Cog score. ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive
Time frame: Week 7, 12
Korean-Mini Mental State Examination-2nd Edition(K-MMSE-2)(Efficacy)
Change from Baseline to 7, 12 and 24 weeks in K-MMSE-2. K-MMSE-2: Korean-Mini Mental State Examination-2nd Edition
Time frame: Week 7, 12, 24
Clinical Dementia Rating(CDR)(Efficacy)
Change from Baseline to 7, 12 and 24 weeks in CDR. CDR: Clinical Dementia Rating
Time frame: Week 7, 12, 24
Global Deterioration Scale(GDeps)(Efficacy)
Change from Baseline to 7, 12 and 24 weeks in GDeps. GDeps: Global Deterioration Scale
Time frame: Week 7, 12, 24
Clinical Global Impression of Change(CGIC)(Efficacy)
Change from Baseline to 7, 12 and 24 weeks in CGIC CGIC: Clinical Global Impression of Change
Time frame: Week 7, 12, 24
Korean-Instrumental Activities of Daily Living(K-IADL)(Efficacy)
Change from Baseline to 7, 12 and 24 weeks in K-IADL. K-IADL: Korean-Instrumental Activities of Daily Living
Time frame: Week 7, 12, 24
Adverse events(AE's)(Safety)
Adverse events (AE's), including serious adverse events (SAEs) occurring at any time during the trial and follow-up.
Time frame: Week 24
Started May 2023 (actual). Primary completion is estimated for Jan 2027, 44 months after the start.
Of 77 industry-sponsored interventional studies with no phase under Alzheimer Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 44 months is above that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.